Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795388 | 0.92 | SIGMAR1 (0.50) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL7939387 | 0.89 | IDO1 (0.56) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL7568412 | 0.89 | IDO1 (0.56) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL10430031 | 0.89 | IDO1 (0.56) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL28776424 | 0.89 | SIGMAR1 (0.44) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL22245646 | 0.89 | PAM (0.48) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL97322 | 0.89 | PAM (0.48) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL6688225 | 0.89 | SIGMAR1 (0.49) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL9480916 | 0.89 | SIGMAR1 (0.44) | IDO1PAMSIGMAR1MAOBHTR2A | |
| SCHEMBL1323652 | 0.86 | IDO1 (0.50) | IDO1PAMSIGMAR1MAOBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | claimed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | claimed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | claimed |
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080292993-A1 | PHOTO-CATIONIC POLYMERIZABLE EPOXY RESIN COMPOSITION, LIQUID DISCHARGE HEAD, AND MANUFACTURING METHOD THEREOF | CANON KABUSHIKI KAISHA (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | disclosed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1144372-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | IDO1 317/4885PAM 481/4885SIGMAR1 1224/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | IDO1 1529/4885PAM 1405/4885SIGMAR1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.